October 2024

SHANGHAI, Oct. 25, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, throu

– Encouraging preliminary anti-tumor activity observed in heavily pre-treated population – – At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity – – P

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: